JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.